Patients with primary thyroid cancer who received radioactive iodine therapy have elevated risks for melanoma and other nonkeratinocyte skin cancers, according to study findings published in JAMA Network Open.
2024
FDA Grants Fast Track Designation to IMM-1-104 for Advanced Melanoma
The FDA granted a fast track designation to IMM-1-104 (Immuneering Corp.) to treat patients with unresectable or metastatic NRAS-mutant melanoma whose disease progressed or is intolerant to PD-1-/PD-L1-based immune checkpoint inhibitors.1 Currently, the treatment is undergoing evaluation in a phase 2a clinical trial (NCT05585320)2, which enrolled patients with advanced solid tumors, including melanoma.
Does Indoor Tanning Affect Melanoma Tumor Mutational Burden?
Indoor tanning exposure was not associated with tumor mutational burden (TMB) in patients with cutaneous melanoma, in a retrospective cohort study. Higher TMB was linked to older age, head and neck tumors, and a history of nonmelanoma skin cancer (NMSC).
Medical mismanagement may contribute to worse survival outcomes for invasive melanoma
Patients with upstaged tumors saw an overall mortality rate of 36% vs. 19.5% in their non-upstaged counterparts.